Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE) announced its participation in a fireside chat at the Citizens Life Sciences Conference in New York on May 8, 2025. CEO Daniel Passeri will present from 11:00 AM to 11:25 AM EDT, discussing progress on the company's Immuno-STAT™ platform programs, including the CUE-100 series, CUE-401, and CUE-501. The presentation will highlight their recent partnership with Boehringer Ingelheim for CUE-501, focusing on T cell mediated targeted depletion of specific B cells for treating autoimmune and inflammatory diseases. A live webcast will be available, and the recording will be archived for 30 days on the company's website.

News Market Reaction – CUE

+3.40%

1 alert

+3.40% News Effect

On the day this news was published, CUE gained 3.40%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Citizens Life Sciences Conference being held in New York, May 7-8, 2025.

During the fireside chat, Cue Biopharma will discuss progress on its programs from the Immuno-STAT™ platform including the CUE-100 series, CUE-401, and CUE-501, which was recently partnered with Boehringer Ingelheim for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases.

Citizens Life Sciences Conference
Presentation Date: Thursday, May 8, 2025
Presentation Time: 11:00 a.m. EDT – 11:25 a.m. EDT
Presenter: Daniel Passeri, Chief Executive Officer
Webcast Link: https://wsw.com/webcast/jmp64/cue/1531757

A live and archived webcast of the fireside chat will be available in the News and Publications section of the Company’s website. The webcast will be archived for 30 days.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.

For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.

Investor Contact
Marie Campinell 
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com

Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com

FAQ

When is Cue Biopharma (CUE) presenting at the Citizens Life Sciences Conference 2025?

Cue Biopharma will present on Thursday, May 8, 2025, from 11:00 AM to 11:25 AM EDT.

What will Cue Biopharma discuss during their Citizens Life Sciences Conference presentation?

They will discuss progress on their Immuno-STAT™ platform programs, including the CUE-100 series, CUE-401, and CUE-501, as well as their partnership with Boehringer Ingelheim.

Who is presenting for Cue Biopharma at the Citizens Life Sciences Conference?

Daniel Passeri, Chief Executive Officer of Cue Biopharma, will be presenting at the conference.

What is the recent partnership between Cue Biopharma (CUE) and Boehringer Ingelheim?

The partnership focuses on CUE-501 for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases.